CTA is governed by a Board of Directors who are responsible for the strategic direction of the organisation, the Corporate Governance and the management of the Chief Executive Officer. The Board comprises eight members, five of whom are nominated by the member institutions, and three who are independently appointed by the Board.
Professor Andrew Scott AM is the current Board Chairperson, and has had significant experience in the management and strategic direction of CTA thorough his previous role as Board member.
Board members bring a mix of skills required to contribute to the strategic direction of an organisation acting as a sevice provider in the field of clinical trial management.
Chairperson: Professor Andrew Scott AM
Research Institutes representative
MBBS MD FRACP FAHMS FAANMS FAICD DDU
Andrew currently holds the positions of Scientific Director of PET, Department of Molecular Imaging and Therapy, Austin Health, and Laboratory Head at the Olivia Newton-John Cancer Research Institute. He is one of Australia’s top clinician/scientists with great experience in both preclinical and clinical drug development. In addition, he is on the Board of many significant organisations including the Australian Nuclear Science and Technology Organisation (ANSTO), World Federation of Nuclear Medicine and Biology, of which he is the current President, and Chair of the International Relations Committee, Australian and New Zealand Society of Nuclear Medicine (ANZSNM). He is also a Fellow of the Australian Institute of Company Directors.
Andrew has published over 260 peer reviewed papers and 20 book chapters, principally in the areas of oncology and molecular imaging. Invited reviews in leading journals include Nature Reviews Cancer and Cancer Research. He is actively involved in the training and mentoring of young scientists and clinicians and currently supervises several doctoral students in addition to post-doctoral fellows and Nuclear Medicine trainees.
Dr John F. Seymour AM
Metropolitan Sites representative
FAHMS MB BS PhD FRACP
Professor John Seymour AM is a clinical haematologist and Associate Director of Clinical Research at the Peter MacCallum Centre, and the Director of the integrated Haematology Department of the Peter MacCallum Cancer Centre & the Royal Melbourne Hospital in Melbourne, Australia.
After receiving his MB and BS degrees from the University of Melbourne in 1987, Professor Seymour completed a translational research fellowship at the MD Anderson Cancer Center in Houston, and subsequently received their Distinguished Alumnus award in 2011. He also completed PhD studies in the pathobiology of haematopoietic growth factors at the Ludwig Institute for Cancer Research.
Professor Seymour is a member of several national and international scientific committees including, Cancer Australia Advisory Groups, the Scientific Advisory Committee for the International Conference on Malignant Lymphoma, Medical Advisory Board of the Lymphoma Coalition, and the Board of Directors of the International Extranodal Lymphoma Study Group. He served for more than a decade as Executive member and Chairman of the major national clinical trials co-operative group in haematologic malignancies, the Australasian Leukaemia & Lymphoma Group. He is a frequent invited speaker nationally and internationally, is a member of numerous professional societies, an Editor-in-Chief of Leukemia & Lymphoma, and currently on the editorial boards of Blood and the British Journal of Haematology. He has authored 18 book chapters, >500 peer reviewed publications (with >24,000 literature citations), and >700 conference abstracts.
Actively involved in a broad range of collaborative research, Professor Seymour has been has been the principal investigator on >85 clinical trials and chief investigator on competitive grants awarded >AUD$18 million funding in the last 10 years. In 2015 he was awarded Membership of the Order of Australia, and elected to the Australian Academy of Health and Medical Sciences for his contributions to the field.
Dr Mark Shackleton
Metropolitan Sites representative
MBBS PhD FRACP
Prof Mark Shackleton is the Director of Oncology at Alfred Health, a Professor of Oncology at Monash University, a Victorian Cancer Agency Clinical Research Fellow, Chair of the Australian and New Zealand Melanoma Trials Group and Head of the Cancer Development and Treatment Laboratory at the Monash Central Clinical School at Alfred. After training in medical oncology and at the Ludwig Institute in Melbourne, Dr. Shackleton undertook PhD studies at the Walter and Eliza Hall Institute of Medical Research and post-doctoral work at the University of Michigan, USA. He was awarded the 2006 Victorian Premier’s Award for Medical Research, a 2010 NHMRC Achievement Award, a 2011 Pfizer Australia Fellowship, and in 2012 was awarded the Australian Science Minister’s Prize for Life Scientist of the Year. His laboratory focuses on understanding mechanisms of cancer initiation and propagation.
Associate Professor Zee Wan Wong
Metropolitan Sites representative
MBBS MRCP FAMS GDA FRCP FRACP
Zee Wan obtained her postgraduate medical qualifications at the Royal College of Physicians in the United Kingdom (Edinburgh) before completing her Medical Oncology fellowship in the United States of America in 2003. Thereafter, she was a Senior Consultant Medical Oncologist at the National Cancer Centre, Singapore. She obtained her Medical Oncology Fellowship with the Royal Australasian College of Physicians in 2013 when she came to Australia. More recently, she completed a Specialist Certificate in Clinical Leadership at The University of Melbourne in 2017.
Previously, Zee Wan was the founding Clinical Director of Oncology Unit at Goulburn Valley Health in Shepparton from 2012 to 2017 as well as the Clinical Director of West Hume Regional Integrated Cancer Services. Her team set up the Oncology Clinical Trial unit within GV Health where they have become a CTA member site and run multiple oncology clinical trials including international phase III studies now through the Velos platform supported by CTA. She was the lead applicant for the Victorian Lung Cancer Redesign Project where Hume was one of two regional sites in Victoria to have been awarded. Zee Wan was also the co-applicant for the Victorian Regional Cancer Clinical Trials Network project awarded by Cancer Council Victoria. In addition, she was the principal investigator for various oncology clinical trials and had actively represented Regional Victoria in several cancer improvement initiatives. She regularly lectures at the Living with Cancer and Cancer Survivorship workshops.
Peninsula Health has been awarded with the Victorian Cancer Survivorship Grant this year where Zee Wan is the lead applicant. She is a member of the AGITG Lower GI Working Party as well as the Prostate Cancer Subcommittee of ANZUP. Furthermore, she also holds memberships with ASCO, ESMO, MOGA, COSA, BCT, ALTG and ANZGOG. She has numerous peer-reviewed publications and presented at national as well as international oncology conferences.
Dr Craig Underhill
Regional Sites representative
Dr Craig Underhill is the Clinical Director of Cancer Services at Albury Wodonga Health and Hume Regional Cancer Service Border East, has a conjoint appointment as a Senior Lecturer with the University of NSW Rural Clinical School Albury, Honorary appointment at Royal Melbourne Hospital as Associate Medical Oncologist, is Chair and Cancer Advisor Cancer Executive Committee, Murrumbidgee Local Health Network, and the Regional Oncology Lead with the Victorian Comprehensive Cancer Centre. Dr Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He became a Fellow of the Royal Australasian College of Physicians in 1997, in the mid 90’s Dr Underhill worked as the Senior Clinical Research Registrar at Guy’s Hospital, London and the Peter MacCallum Cancer Institute Melbourne.
In 1999 Dr Underhill was the founding partner in the Medical Oncology Practice (Border Medical Oncology) and established a Clinical Trials Unit (Border Medical Oncology Research Unit), has VMO appointments at Albury Wodonga Health ( Albury and Wodonga Campuses) Murray Valley Private Hospital, and Albury-Wodonga Private Hospital. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials and chaired a working party that was instrumental in securing $65 million in federal funding for the Albury Wodonga Regional Cancer Centre, which opened in 2016.
Dr Underhill has developed partnerships with the private sector to improve access to cancer services and fostered shared care arrangements between local public and private health care providers, has also built linkages and referral pathways between metropolitan and regional centres as evidenced by the development of multidisciplinary meetings. His achievements in research collaborations have led to changes in practice in the care of patients with cancer, including the introduction of new standards and models of care.
BAppSc GradCertMarketing GradDipBusiness (Public Relations)
Michelle is CEO of ShareRoot, an ASX listed technology development company. With over 25 years of experience in the biopharmaceuticals and healthcare sector and deep professional global networks, Michelle is a recognised, award-winning leader in the Australian innovation industries. Establishing The Social Science in 2014, selling to ShareRoot in April 2018 and guiding a specialist application of ShareRoot’s key platform technology, Media Consent, in the medical sector, Michelle has a proven track record of business building, creative disruption and commercialisation of technologies. Michelle is co founder of NFP Women in STEMM Australia and a recognised advocate for gender equality and diversity in STEMM industries. Previously CEO of the Victorian biotechnology industry association, director of external relations at the Australian Stem Cell Centre, Michelle is a NED on a number of NFP and for profit organisations in the biotech, medick and health sector.
Michelle holds an allied health qualification in Applied Science from La Trobe University as well as postgraduate qualifications in Business from RMIT University and Executive Leadership and GEMBA from Monash University. Michelle is also co-founder of Women in STEMM Australia, Telstra Victorian Business Woman of the Year and Entrepreneur of the Year in 2017 and was inducted into the Victorian Honour Roll for Women in 2018.
See more at: http://thesocialscience.com.au/
BCom CA(SA) ACA
Colin joined the CTA Board in June 2015.
Colin is a current member of the Aust & NZ Inst of Chartered Accountants and owns a consulting practice offering strategic and financial services to the healthcare sector.
Colin is a “Big 4” trained Chartered Accountant, graduated from the University of Cape Town and gaining his CA (SA) membership. He obtained his Australian ACA accreditation in 1983.
Colin has extensive commercial and technical experience across a broad range of national and global companies. The last 25 years have been spent in the Healthcare space with companies such as Ipsen, Kendle (now INC Research ) , Medisence (Abbott Labs), holding Financial Director and Board positions in these and other organisations.
BSc(Hons), M Mkt, FAICD
Tim Murphy is currently the General Manager of Blood Cancer Partnerships at the Leukaemia Foundation. A politically astute executive with extensive experience working with both the C-suite and Boardroom to manage corporate issues in regulated environments. Tim has demonstrated leadership ability in creating corporate vision and the accomplishment of goals through the motivation and direction of others. Tim has broad local and international experience in effective stakeholder engagement and political advocacy, with a strong background in high growth, merger, consolidation, and downsizing global and national businesses. His expertise crosses multiple sectors, including healthcare.
Tim’s a passionate strategic thinker who develops high performing teams and works cross-functionally to ensure the long-term viability of organisations. Tim is a Fellow of the Australian Institute of Company Directors, and has a Bachelor of Science (Hons) and a Master of Marketing from Melbourne Business School.
Tim is currently the Chairperson of ARMI, and his recent career history includes Director, Global Strategic Initiatives, ViiV Healthcare and Head – Government Affairs, Global Market Development, GSK Vaccines, Brussels.
Dr Kurt Lackovic
CEO and Board Secretary
BAppSc (Hons) PhD MBA GAICD
Dr Lackovic commenced as CEO of Cancer Trials Australia in January 2017.
Kurt has a PhD in chemistry, MBA from Melbourne Business School, is a graduate of the Australian Institute of Company Directors, and a member of the Licensing Executives Society of Australia and New Zealand, AusBiotech and the NHMRC Research Translation Faculty.
Kurt has extensive experience in leading complex academic and clinical programs, strong connections to industry, and strategic linkages to senior executives in Government and major teaching Hospitals. In previous roles he has worked in early stage drug discovery with a focus on oncology targets, managed the Walter and Eliza Hall Institute’s High Throughput Screening Facility, led multiple Cancer Therapeutics CRC projects involving national and international partners, and has overseen day-to-day management of the Melbourne Genomics Health Alliance.